NVCT

Nuvectis Pharma, Inc. (NVCT) | Rumor.io

Nuvectis Pharma

NVCT

Attention (50-day avg)0%

Attention rank (50-day avg)#2,244

Bullish sentiment (50-day avg)86%

Price to earnings ratio-15.8

Market capitalization679.3M

Earnings per share-1.32

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-26.4M

Social

What share of all stock conversation is about NVCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 29

The stock price of NVCT is $20.22, down 6.51% from an unspecified earlier price.
Many users are expressing frustration and concern about holding NVCT, with some stating they are "drowning" or "stuck underwater" due to the stock's decline.
Users are seeking companionship and solidarity with others who are also holding NVCT and experiencing losses.

Generated by AI

Sentiment

Of the messages about NVCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +19.7	80.84% -4.06
Bearish	—	—	0% -19.7	19.16% +4.06

Bullish· May 20

NVCT has a high potential for a parabolic increase in price, with the expectation of relentless buying throughout the year.
The company's NXP-800 data is expected to be positive, with a potential price target of $14 this week, and the drug is considered a blockbuster with a massive total addressable market.
The company's recent investor conference was extremely bullish, with the CEO sounding upbeat about the NXP-800 data, and the majority shareholder buying in anticipation of a positive outcome.

Bearish· Jul 31

The asset's short position is extremely high, with 2.6 million shares shorted, which may be trapped due to the recent elimination of the NXP800 overhang.
The company's management may be in cahoots with the short sellers, receiving kickbacks and leaking information to facilitate the short sale.
The asset's stock price has been stagnant for the past 4 years, with no true execution on its development plans, and the recent dilution may be used to fund management's salaries rather than support the company's growth.

Generated by AI

Topics

Of the messages about NVCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	75%	95.65%	67.97%
Technical Analysis	—	0%	0%	14.05%
Analysts	—	25%	4.35%	11.27%
Earnings	—	0%	0%	0.65%
Controversies	—	0%	0%	0.16%
Macro	—	0%	0%	5.88%

Announcements· Jul 23

Nuvectis Pharma's ciprocopan (NXP100) receives marketing approval in China for the treatment of patients with PNH previously untreated with complement inhibitors.
The NMPA in China granted approval to ciprocopan (NXP100) for treatment-naive PNH patients, making it the world's first once-daily oral Complement Factor B inhibitor with marketing approval.
The Phase 3 data showed 94.6% efficacy for ciprocopan (NXP100) in a head-to-head trial against Soliris, meeting the primary and secondary endpoints, and demonstrating its superiority in the PNH market.

Technical Analysis· Feb 7

NVCT is identified as a short opportunity at $9.35 due to a distribution pattern and microfloat characteristics.
The stock has formed a bull pennant and a double bottom on the daily chart, indicating a potential reversal with a cup and handle pattern and momentum.
NVCT has broken out above $9.5, which is now acting as resistance, and may be due for a rocket move if it breaks through.

Generated by AI

Community

Of the messages about NVCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	80%	97.37%	62.64%
Newcomers	—	20%	2.63%	37.36%

Regulars· Jul 23

Ciprocopan (NXP100) has received marketing approval in China for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with complement inhibitors, making it the world's first once-daily oral Complement Factor B inhibitor to clear any major regulator.
The Phase 3 primary endpoint result for ciprocopan against eculizumab, the infused drug standard of care for nearly two decades, was a 59.5% versus 8.3% gap, the widest recorded in a PNH trial pitting a Factor B inhibitor against eculizumab.
This approval marks a significant milestone for Nuvectis Pharma, moving from zero approved drugs to world-first regulatory clearance in a single quarter, and reshaping the Factor B inhibitor competitive narrative, with ciprocopan becoming the only once-daily oral Complement Factor B inhibitor with marketing approval anywhere in the world.

Newcomers· Sep 29

Many users are holding onto NVCT despite its significant drop, with some expressing concern about being "stuck underwater" or "drowning" in their investments.
The majority of users are focused on the pain and suffering they are experiencing due to NVCT's decline, with some seeking "comrades" or "fellow NVCT holders" to share in their misery.
Users are expressing anxiety about the current state of NVCT, with many wondering if they are "not the only one" experiencing this pain, and some hoping to find others who are "in the same boat" or "raising their hand" to show solidarity.

Generated by AI

WSW, NY, September 25th, 2026, FinanceWireThree months ago, Nuvectis Pharma (NASDAQ:NVCT) was an oncology developer anchored by a single early-stage program. Today it holds ex-China rights to the world's first

4d agobenzinga.com

Nuvectis’ NXP200 receives breakthrough therapy status in China

5d agoInvesting.com

Nuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)

12d agoSeeking Alpha

Nuvectis Pharma at H.C. Wainwright conference: pipeline and cash stand out

15d agoInvesting.com

Nuvectis at Cantor healthcare conference: betting on factor B

18d agoInvesting.com

Also Discussed

Investors talking about NVCT also mention

#	Name	Attention
1	Janux Therapeutics, Inc.JANX	0%0
2	Beyond Air, Inc.XAIR	0%0
3	Axsome Therapeutics IncAXSM	0.01%0
4	NeuroSense Therapeutics Ltd.NRSN	0%0
5	F/m 2-Year Investment Grade Corporate Bond ETFZTWO	0%0
6	Vanguard Russell 3000 ETFVTHR	0%new
7	KACL - Kairous Acquisition Corp. Limited	——
8	FIAC - Focus Impact Acquisition Corp.	——
9	F/m US Treasury 7 Year Note ETFUSVN	0%0
10	ProShares Ultra QQQ MegaQQUP	0%0

Nuvectis Pharma, Inc.

Healthcare
Biotechnology

Nuvectis Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for serious oncology conditions with unmet medical need. The company works on targeted small-molecule therapies designed for genetically defined cancer patient populations, with its current pipeline centered on NXP800 and NXP900. NXP800 is being developed for specific ovarian cancer settings, while NXP900 is designed to inhibit SRC family kinases, including SRC and YES1, in solid tumors. Based in Fort Lee, New Jersey, Nuvectis Pharma operates as a single-segment biotechnology business centered on oncology drug development and clinical research.

Website

Location

1 Bridge Plaza

Fort Lee, NJ, 07024

United States

Social

What share of all stock conversation is about NVCT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 29

The stock price of NVCT is $20.22, down 6.51% from an unspecified earlier price.
Many users are expressing frustration and concern about holding NVCT, with some stating they are "drowning" or "stuck underwater" due to the stock's decline.
Users are seeking companionship and solidarity with others who are also holding NVCT and experiencing losses.

Generated by AI

Sentiment

Of the messages about NVCT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% +19.7	80.84% -4.06
Bearish	—	—	0% -19.7	19.16% +4.06

Bullish· May 20

NVCT has a high potential for a parabolic increase in price, with the expectation of relentless buying throughout the year.
The company's NXP-800 data is expected to be positive, with a potential price target of $14 this week, and the drug is considered a blockbuster with a massive total addressable market.
The company's recent investor conference was extremely bullish, with the CEO sounding upbeat about the NXP-800 data, and the majority shareholder buying in anticipation of a positive outcome.

Bearish· Jul 31

The asset's short position is extremely high, with 2.6 million shares shorted, which may be trapped due to the recent elimination of the NXP800 overhang.
The company's management may be in cahoots with the short sellers, receiving kickbacks and leaking information to facilitate the short sale.
The asset's stock price has been stagnant for the past 4 years, with no true execution on its development plans, and the recent dilution may be used to fund management's salaries rather than support the company's growth.

Generated by AI

Topics

Of the messages about NVCT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	75%	95.65%	67.97%
Technical Analysis	—	0%	0%	14.05%
Analysts	—	25%	4.35%	11.27%
Earnings	—	0%	0%	0.65%
Controversies	—	0%	0%	0.16%
Macro	—	0%	0%	5.88%

Announcements· Jul 23

Nuvectis Pharma's ciprocopan (NXP100) receives marketing approval in China for the treatment of patients with PNH previously untreated with complement inhibitors.
The NMPA in China granted approval to ciprocopan (NXP100) for treatment-naive PNH patients, making it the world's first once-daily oral Complement Factor B inhibitor with marketing approval.
The Phase 3 data showed 94.6% efficacy for ciprocopan (NXP100) in a head-to-head trial against Soliris, meeting the primary and secondary endpoints, and demonstrating its superiority in the PNH market.

Technical Analysis· Feb 7

NVCT is identified as a short opportunity at $9.35 due to a distribution pattern and microfloat characteristics.
The stock has formed a bull pennant and a double bottom on the daily chart, indicating a potential reversal with a cup and handle pattern and momentum.
NVCT has broken out above $9.5, which is now acting as resistance, and may be due for a rocket move if it breaks through.

Generated by AI

Community

Of the messages about NVCT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	80%	97.37%	62.64%
Newcomers	—	20%	2.63%	37.36%

Regulars· Jul 23

Ciprocopan (NXP100) has received marketing approval in China for the treatment of patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) previously untreated with complement inhibitors, making it the world's first once-daily oral Complement Factor B inhibitor to clear any major regulator.
The Phase 3 primary endpoint result for ciprocopan against eculizumab, the infused drug standard of care for nearly two decades, was a 59.5% versus 8.3% gap, the widest recorded in a PNH trial pitting a Factor B inhibitor against eculizumab.
This approval marks a significant milestone for Nuvectis Pharma, moving from zero approved drugs to world-first regulatory clearance in a single quarter, and reshaping the Factor B inhibitor competitive narrative, with ciprocopan becoming the only once-daily oral Complement Factor B inhibitor with marketing approval anywhere in the world.

Newcomers· Sep 29

Many users are holding onto NVCT despite its significant drop, with some expressing concern about being "stuck underwater" or "drowning" in their investments.
The majority of users are focused on the pain and suffering they are experiencing due to NVCT's decline, with some seeking "comrades" or "fellow NVCT holders" to share in their misery.
Users are expressing anxiety about the current state of NVCT, with many wondering if they are "not the only one" experiencing this pain, and some hoping to find others who are "in the same boat" or "raising their hand" to show solidarity.

Generated by AI

Nuvectis Pharma

Social

Sep 29

Bullish· May 20

Bearish· Jul 31

Announcements· Jul 23

Technical Analysis· Feb 7

Regulars· Jul 23

Newcomers· Sep 29

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead

Nuvectis’ NXP200 receives breakthrough therapy status in China

Nuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)

Nuvectis Pharma at H.C. Wainwright conference: pipeline and cash stand out

Nuvectis at Cantor healthcare conference: betting on factor B

Also Discussed

Nuvectis Pharma, Inc.

Company Information

Location

Nuvectis’ In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It’s Not Even Their Lead Asset

Nuvectis' In-Licensed Cancer Drug Earned Breakthrough Designation in China, and It's Not Even Their Lead

Nuvectis’ NXP200 receives breakthrough therapy status in China

Nuvectis Pharma:Haisco Licensing Deal Revitalises Biotech, But No Rush To Invest Now(NVCT)

Nuvectis Pharma at H.C. Wainwright conference: pipeline and cash stand out

Nuvectis at Cantor healthcare conference: betting on factor B

Also Discussed

Social

Sep 29

Bullish· May 20

Bearish· Jul 31

Announcements· Jul 23

Technical Analysis· Feb 7

Regulars· Jul 23

Newcomers· Sep 29